Shandong Keyuan Pharmaceutical Co. Ltd. A
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more
Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) - Net Assets
Latest net assets as of June 2025: CN¥1.38 Billion CNY
Based on the latest financial reports, Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has net assets worth CN¥1.38 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.60 Billion) and total liabilities (CN¥222.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.38 Billion |
| % of Total Assets | 86.15% |
| Annual Growth Rate | 46.65% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 68.64 |
Shandong Keyuan Pharmaceutical Co. Ltd. A - Net Assets Trend (2021–2024)
This chart illustrates how Shandong Keyuan Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual net assets of Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.36 Billion | +2.15% |
| 2023-12-31 | CN¥1.33 Billion | +156.10% |
| 2022-12-31 | CN¥519.73 Million | +20.59% |
| 2021-12-31 | CN¥430.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Keyuan Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 106.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥290.05 Million | 21.35% |
| Other Components | CN¥1.07 Billion | 78.65% |
| Total Equity | CN¥1.36 Billion | 100.00% |
Shandong Keyuan Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shandong Keyuan Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viva Biotech Holdings
PINK:VBIZF
|
$304.96 Million |
|
Prism Johnson Limited
NSE:PRSMJOHNSN
|
$305.09 Million |
|
SOLiD Inc
KQ:050890
|
$305.10 Million |
|
ECOVE Environment Corp
TWO:6803
|
$305.16 Million |
|
Takamatsu Construction Group Co., Ltd.
PINK:TAKMF
|
$304.85 Million |
|
0N01
LSE:0N01
|
$304.75 Million |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
$304.68 Million |
|
Zhong Fu Tong Co Ltd
SHE:300560
|
$304.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Keyuan Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,331,040,248 to 1,358,795,635, a change of 27,755,387 (2.1%).
- Net income of 60,448,712 contributed positively to equity growth.
- Dividend payments of 32,562,969 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥60.45 Million | +4.45% |
| Dividends Paid | CN¥32.56 Million | -2.4% |
| Other Changes | CN¥-130.36K | -0.01% |
| Total Change | CN¥- | 2.09% |
Book Value vs Market Value Analysis
This analysis compares Shandong Keyuan Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.51x to 4.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥5.31 | CN¥50.45 | x |
| 2022-12-31 | CN¥6.40 | CN¥50.45 | x |
| 2023-12-31 | CN¥12.29 | CN¥50.45 | x |
| 2024-12-31 | CN¥12.55 | CN¥50.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Keyuan Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.04%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.14x
- Recent ROE (4.45%) is below the historical average (11.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 18.14% | 18.57% | 0.75x | 1.30x | CN¥35.07 Million |
| 2022 | 17.56% | 20.61% | 0.68x | 1.25x | CN¥39.31 Million |
| 2023 | 5.79% | 17.21% | 0.30x | 1.10x | CN¥-56.06 Million |
| 2024 | 4.45% | 13.04% | 0.30x | 1.14x | CN¥-75.43 Million |
Industry Comparison
This section compares Shandong Keyuan Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,443,093,618
- Average return on equity (ROE) among peers: -7.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) | CN¥1.38 Billion | 18.14% | 0.16x | $304.87 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $177.19 Million | 13.55% | 0.63x | $201.14 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $280.61 Million | 7.70% | 0.99x | $310.45 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $638.18 Million | -181.03% | 3.22x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $477.68 Million | 3.28% | 0.64x | $234.89 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $361.29 Million | 26.02% | 0.32x | $146.91 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.03 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $278.08 Million | 2.72% | 0.13x | $459.10 Million |
| Chongqing Lummy Pharmaceutical (300006) | $107.91 Million | 22.70% | 0.99x | $476.38 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.44 Billion | 5.91% | 0.29x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $1.53 Billion | 18.22% | 0.05x | $893.48 Million |